New WHO Director Calls On Board To Join In “Intensive” Period Of Change 22/01/2018 by Catherine Saez, Intellectual Property Watch 1 Comment All human beings should receive the health services they need without suffering financial hardship, such is the definition of universal health coverage, a key point of discussion at the World Health Organization Executive Board meeting this week. New WHO Director General Tedros Adhanom Ghebreyesus (Dr Tedros) opened the event by presenting his vision for the future, and the collective work to accomplish necessary changes to the UN health agency. The European Union and United States warned against politicisation of the WHO.
US Working To Block UN High-Level Panel On Access To Medicines Ideas In Geneva And Capitals 22/01/2018 by William New, Intellectual Property Watch Leave a Comment The United States, possibly working with like-minded countries, is working to prevent the further spread among international organisations in Geneva of recommendations put forward by the 2016 United Nations High-Level Panel on Access to Medicines, considering them to be ideological driven and dangerous to economic growth. The comments were made by a US official speaking to a recent US industry event in Washington DC involving many of the US intellectual property attachès, at which two attachés from Geneva described latest developments and strategy for the coming year. A key message from attachès to industry: come to Geneva and engage, starting with this week’s Executive Board meeting at the World Health Organization.
Moving Landscape In The IP World – Organisations, Industry, Law Firms 19/01/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The end of 2017 and start of 2018 brought a lot of changes in the global intellectual property arena. The World Health Organization underwent major changes in its leadership following a new head elected in May, UNAIDS has a new deputy executive director, the World Intellectual Property Organization is seeking a new leader of its Global Challenges division, and the Board of the Internet Corporation for Assigned Names and Numbers decided on a number of appointments. The European Patent Office elected a new president, and the industry world also saw its share of changes. The International Federation of Pharmaceutical Manufacturers and Associations welcomed some new faces, and the head of the Federation of the European Sporting Goods Industry is changing. Law firms saw a high level of revolving chair movements, and promotions of attorneys to partners.
Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says 19/01/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that the industry can continue its efforts sustainably. Some light was also shed on the need to support access to diagnostics, and lower their prices.
Heading Off Global Action On Access To Medicines In 2018 19/01/2018 by Intellectual Property Watch Leave a Comment At the dawn of 2018, political and health leaders must seize the growing momentum and opportunities to tackle the protracted challenges of access to medicines that undermines efforts to save lives and improve health as committed under the Agenda 2030 SDG [Sustainable Development Goals] by all UN member states, write Jorge Bermudez and Viroj Tangcharoensathien.
Global Summit On IP And Access Discusses Impact Of TRIPS-Plus Measures On Public Health 17/01/2018 by Catherine Saez, Intellectual Property Watch 10 Comments A network of civil society organisations chose the birthplace of the World Trade Organization, Marrakesh, to hold a global summit on intellectual property and access to medicines this week. Part of the summit focused on stringent IP measures in free trade agreements in particular with the European Union, introducing patent term extension and data exclusivity periods.
Guide To The WHO Executive Board: Access To Medicines, Noncommunicable Diseases, Non-State Actors 15/01/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Health Organization Executive Board meets next week. On the agenda are recommendations of a review group on the WHO Global Strategy on Public Health, Innovation and Intellectual Property, and WHO proposed actions to increase access to affordable and safe medicines and diagnosis. The Executive Board is also expected to consider a report on noncommunicable diseases, new possible organisations to enter into official relationships with WHO, and how to address the global burden of snakebites, including access to treatment.
New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 by Justus Wanzala for Intellectual Property Watch Leave a Comment Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!]
How International IP Policy Reconfigured National Politics: An Interview With Prof. Ken Shadlen 11/01/2018 by Intellectual Property Watch 3 Comments The recently published book Coalitions and Compliance by Professor Ken Shadlen of the London School of Economics examines how international changes can reconfigure domestic politics. Since the late 1980s, developing countries have been subject to intense pressures regarding intellectual property rights. These pressures have been exceptionally controversial in the area of pharmaceuticals. Historically, fearing the economic and social costs of providing private property rights over knowledge, developing countries did not allow drugs to be patented. Now they must do so, an obligation with significant implications for industrial development and public health. This book analyses different forms of compliance with this new imperative in Latin America, comparing the politics of pharmaceutical patenting in Argentina, Brazil, and Mexico. The book focuses on two periods of patent politics: initial conflicts over how to introduce drug patents, and then subsequent conflicts over how these new patent systems function. Intellectual Property Watch recently conducted a Q&A with Prof. Shadlen, which appears below.
WTO Stalemate Concerns Include Non-Violation Complaints, E-Commerce; TRIPS Health Amendment Extended 08/01/2018 by Monika Ermert for Intellectual Property Watch Leave a Comment A few weeks after the failure of the World Trade Organization ministerial meeting in Buenos Aires to cut deals advancing issues from fisheries to e-commerce, some governments and trade experts around the world are concerned about the WTO’s future. Meanwhile, a couple of intellectual property-related provisions moved ahead after the ministerial without change.